Anti-Cancer and Other Health-Promoting Effects of Silibinin and Silibinin Derivatives
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 11758
Special Issue Editors
2. Catalan Institute of Oncology (ICO)-Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain
Interests: cancer; metabolism; metformin; aging; drug development
Special Issues, Collections and Topics in MDPI journals
2. Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Catalonia, Spain
Interests: lung cancer; brain metastasis; bioactive compounds
Special Issues, Collections and Topics in MDPI journals
2. Metabolism & Cancer Group, Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain
Interests: cancer; metabolism; metformin; aging; drug development
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The flavonolignan silibinin (or silybin) is considered the major bioactive component of silymarin, an extract of Silybum marianum (milk thistle) seeds that was classified by the World Health Organization in the 1970s as an official medicine with health-promoting properties. The well-known hepatoprotective, anti-inflammatory, and anti-fibrotic effects of silibinin have supported the therapeutic use of silymarin for the treatment of liver illnesses such as alcoholic liver disease, nonalcoholic liver disease, drug-induced liver injury, cirrhosis, viral hepatitis, and mushroom poisoning over the last 50 years.
In the last decade, an ever-growing number of preclinical studies have illuminated the potential anti-cancer effects of silibinin. Silibinin has been shown to exert significant tumoricidal activity against cultured cancer cells and xenografts, to enhance the efficacy of other anti-cancer therapeutic agents, to reduce the toxicity of cancer treatments, and to prevent and overcome the emergence of cancer drug resistance. However, the achievement of a bona fide, clinically relevant anti-cancer activity of silibinin remains controversial in human trials. Thus, whereas no significant anti-tumor activity of silibinin has been reported in prostate cancer tissues, certain silibinin-containing formulations have been successfully applied to lung cancer patients with established brain metastases, providing highly significant survival advantages, low toxicity and reversible secondary effects, and compatibility with the standard-of-care.
To encompass the remarkable breadth of ongoing investigation on silibinin and cancer, research articles, review articles as well as short communications covering a wide range of topics related to the therapeutic application of silibinin as an anti-cancer treatment, including but not limited to molecular mechanisms, signaling pathways, metabolism, pre-clinical studies, drug formulations, analogues, drug combinations, immune response, and clinical trials are welcomed for inclusion in this Special Issue of Pharmaceuticals. Manuscripts reporting on the health-promoting effects and molecular bases of silibinin (or other components of silymarin and its derivatives) for aging-related chronic diseases such as obesity, type 2 diabetes, metabolic syndrome, chronic respiratory diseases, cardiovascular diseases, neurodegenerative diseases, as well as viral infections including SARS-CoV-2/COVID-19 will also be welcomed in the issue.
Dr. Javier A. Menendez
Dr. Joaquim Bosch-Barrera
Dr. Elisabet Cuyàs Navarro
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- silibinin (or silybin)
- Silymarin and Derivatives
- Molecular mechanisms of action
- Cellular mechanisms of action
- Metabolism and bioavailability
- Drug development
- Analogs
- Pre-clinical studies
- Metastasis
- Immune system
- Clinical trials
- Epidemiology
- Obesity
- Type 2 diabetes
- Metabolic syndrome
- Chronic respiratory diseases
- Chronic obstructive pulmonary disease
- Asthma
- Pulmonary hypertension
- Cardiovascular disease
- Myocardial infarction
- Hypertension
- Neurogenerative diseases
- Amyotrophic lateral sclerosis
- Parkinson’s diseases
- Alzheimer’s disease
- Huntington’s disease
- Viral infections
- HIV
- SARS-CoV2
- COVID-19
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
